🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Placebo matching REGN7508, REGN7508

    Lacuna Pharma Pty Ltd

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial

  2. Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized), ustekinumab, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (authorized - MA number: 6697366.00.00), bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  3. Placebo matching to garetosmab, Garetosmab

    Lacuna Pharma Pty Ltd

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  4. Placebo matching to spesolimab

    Boehringer Ingelheim

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  5. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN THERAPEUTICS INC

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial

  6. Placebo of Eliquis 2.5 mg, Eliquis 2.5 mg film-coated tablets

    Pari Pharma GmbH

    Intrahepatic non-cirrhotic portal hypertension

    phase 3 small molecule active

    1 trial

  7. Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg

    Amneal Pharma Europe Ltd

    Uncomplicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  8. Placebo of Procoralan 5 mg, Procoralan 5 mg film-coated tablets

    Pari Pharma GmbH

    Septic shock

    phase 3 small molecule active

    1 trial

  9. Placebo of XEOMIN 100UY, powder for injection, XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    incisional hernia

    phase 3 small molecule active

    1 trial

  10. Placebo of ZIMINO (glucose 5%), ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  11. Placebo of Zodasiran, ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule active

    1 trial

  12. Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension

    AstraZeneca AB

    Severe and inadequately controlled asthma

    phase 3 small molecule active

    1 trial

  13. Placebo solution for IV infusion, ARGX-117, HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo solution for IV infusion, HUMAN NORMAL IMMUNOGLOBULIN (IV)

    argenx

    Multifocal Motor Neuropathy

    phase 3 small molecule active

    1 trial

  14. Placebo tablet matching acetylsalicylic acid, MIGOUTINE 0,5 mg, comprimé pelliculé, ACETYLSALICYLIC ACID , Placebo tablet matching migoutine 0,5 mg, comprimé pelliculé

    The George Institute

    Type 2 diabetic patients with no prior cardiovascular (CV) events

    phase 3 small molecule active

    1 trial

  15. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  16. Placebo tablets to match S95032 drug product are supplied as white to off-white, round (10 mg) and white to off-white oblong (40 mg) film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    The George Institute

    Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

    phase 3 small molecule active

    1 trial

  17. Placebo tablets without active pharmaceutical ingredient closely resembling the imp, Hetrombopag Olamine

    Lacuna Pharma Pty Ltd

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  18. Placebo tablets, ELENESTINIB, ELENESTINIB, ELENESTINIB, ELENESTINIB

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis and SSM

    phase 3 small molecule active

    1 trial

  19. Placebo tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

  20. Placebo to 100mg masitinib, Placebo to 200mg masitinib, masitinib, masitinib

    AB Science

    Mastocytosis

    phase 3 small molecule active

    1 trial

  21. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  22. Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  23. Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Pharmaceuticals

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  24. Placebo to ARGX-113 solution for injection, ARGX-113

    argenx

    Active Idiopathic Inflammatory Myopathy (IIM)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources